FAGRON N.V. |
Market Closed -
Other stock markets
|
After market 01:30:00 am | |||
| 18.2 EUR | +2.48% |
|
18.18 | -0.11% |
| 11/04 | Transcript : Fagron NV, Q1 2024 Sales/ Trading Statement Call, Apr 11, 2024 | |
| 11/04 | Fagron Reports Revenue Results for the First Quarter Ended 31 March 2024 | CI |
Business Summary
Number of employees: 3,282
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Fagron North America
40.5
%
| 245 | 35.8 % | 309 | 40.5 % | +25.99% |
Fagron EMEA
37.3
%
| 276 | 40.4 % | 285 | 37.3 % | +3.08% |
Fagron Latin America
22.2
%
| 162 | 23.7 % | 169 | 22.2 % | +4.25% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
North America
40.5
%
| 245 | 35.8 % | 309 | 40.5 % | +25.99% |
EMEA
37.3
%
| 276 | 40.4 % | 285 | 37.3 % | +3.08% |
Latin America
22.2
%
| 162 | 23.7 % | 169 | 22.2 % | +4.25% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 27/17/27 | |
Karin de Jong
DFI | Director of Finance/CFO | 45 | 01/08/01 |
Vera Bakker
COO | Chief Operating Officer | 52 | 09/22/09 |
Karen Berg
IRC | Investor Relations Contact | - | 01/21/01 |
Marc van der Aa
PRN | Corporate Officer/Principal | - | - |
Johan Verlinden
LAW | General Counsel | - | 01/13/01 |
| Corporate Officer/Principal | 54 | 01/08/01 | |
Celine Caveye
HRO | Human Resources Officer | - | 01/11/01 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Koen Hoffman
CHM | Chairman | 56 | 01/16/01 |
| Director/Board Member | 64 | 01/19/01 | |
| Chief Executive Officer | 46 | 27/17/27 | |
Karin de Jong
DFI | Director of Finance/CFO | 45 | 01/08/01 |
| Director/Board Member | 53 | 09/22/09 | |
Vera Bakker
COO | Chief Operating Officer | 52 | 09/22/09 |
Neeraj Sharma
BRD | Director/Board Member | 52 | 09/22/09 |
| Director/Board Member | 53 | 01/22/01 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 73,228,904 | 69,227,472 ( 94.54 %) | 241,999 ( 0.3305 %) | 94.54 % |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
FAGRON as
 FAGRON as Pharmaceuticals: MajorHealth Technology FAGRON as operates as wholesaler of pharmaceutical raw materials, creams and packaging to pharmacists. The company was founded on May 11, 1992 and is headquartered in Olomouc, Czech Republic. |
Pharmaceuticals: Major
|
Arseus Capital NV
 Arseus Capital NV Financial ConglomeratesFinance Part of Fagron NV, Arseus Capital NV provides financial services. The private company is based in Nazareth, Belgium. The CEO of the Belgian company is Cornelia de Jong. |
Financial Conglomerates
|
Dr. Kulich Pharma sro
 Dr. Kulich Pharma sro Pharmaceuticals: MajorHealth Technology Dr. Kulich Pharma sro engages in the pharmaceuticals industry. It offers drugs, pharmaceutical materials, chemicals, as well as laboratory services. The company was founded by Jan Kulich in 1992 and is headquartered in Hradec Kralove, Czech Republic. |
Pharmaceuticals: Major
|
Fagron BV
|
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.76
EUR
Average target price
21.7
EUR
Spread / Average Target
+22.18%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.57% | 1.38B | |
| +26.47% | 661B | |
| +26.74% | 566B | |
| -6.33% | 352B | |
| +19.35% | 332B | |
| +4.23% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.04% | 145B |
- Stock Market
- Equities
- FAGR Stock
- Company Fagron N.V.
